Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions

Michelle T. Lee; Jerin George; Hunaina Shahab; Melody Hermel; Jamal S. Rana; Salim S. Virani

doi:10.1007/s11883-022-00985-0

Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions

Michelle T. Lee, Jerin George, Hunaina Shahab, Melody Hermel, Jamal S. Rana, Salim S. Virani

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

Abstract

Purpose of Review: This review highlights major studies across a broad array of topics presented at the virtual 2021 American Heart Association (AHA) Scientific Sessions. Recent Findings.: Assessed studies examine a remotely delivered hypertension and lipid program in 10,000 patients across a diverse healthcare network; a cluster-randomized trial of a village doctor-led intervention for hypertension control; empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); efficacy and safety of empagliflozin in hospitalized heart failure patients (EMPULSE); icosapent ethyl versus placebo in outpatients with coronavirus disease 2019 (PREPARE-IT 2); clinical safety, pharmacokinetics, and low-density lipoprotein cholesterol-lowering efficacy of MK-0161, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; and effects of aspirin on dementia and cognitive impairment in the ASCEND trial. Summary: Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention.

Original language	English (US)
Pages (from-to)	61-72
Number of pages	12
Journal	Current Atherosclerosis Reports
Volume	24
Issue number	1
DOIs	https://doi.org/10.1007/s11883-022-00985-0
Publication status	Published - Jan 2022
Externally published	Yes

Keywords

Aspirin
Atherosclerotic cardiovascular disease
Cardiovascular prevention
Empagliflozin
Heart failure

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11883-022-00985-0

Cite this

@article{db4f35be2f07451c9d666878fdc89010,

title = "Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions",

abstract = "Purpose of Review: This review highlights major studies across a broad array of topics presented at the virtual 2021 American Heart Association (AHA) Scientific Sessions. Recent Findings.: Assessed studies examine a remotely delivered hypertension and lipid program in 10,000 patients across a diverse healthcare network; a cluster-randomized trial of a village doctor-led intervention for hypertension control; empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); efficacy and safety of empagliflozin in hospitalized heart failure patients (EMPULSE); icosapent ethyl versus placebo in outpatients with coronavirus disease 2019 (PREPARE-IT 2); clinical safety, pharmacokinetics, and low-density lipoprotein cholesterol-lowering efficacy of MK-0161, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; and effects of aspirin on dementia and cognitive impairment in the ASCEND trial. Summary: Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention.",

keywords = "Aspirin, Atherosclerotic cardiovascular disease, Cardiovascular prevention, Empagliflozin, Heart failure",

author = "Lee, \{Michelle T.\} and Jerin George and Hunaina Shahab and Melody Hermel and Rana, \{Jamal S.\} and Virani, \{Salim S.\}",

note = "Publisher Copyright: {\textcopyright} 2022, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.",

year = "2022",

month = jan,

doi = "10.1007/s11883-022-00985-0",

language = "English (US)",

volume = "24",

pages = "61--72",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions

AU - Lee, Michelle T.

AU - George, Jerin

AU - Shahab, Hunaina

AU - Hermel, Melody

AU - Rana, Jamal S.

AU - Virani, Salim S.

PY - 2022/1

Y1 - 2022/1

N2 - Purpose of Review: This review highlights major studies across a broad array of topics presented at the virtual 2021 American Heart Association (AHA) Scientific Sessions. Recent Findings.: Assessed studies examine a remotely delivered hypertension and lipid program in 10,000 patients across a diverse healthcare network; a cluster-randomized trial of a village doctor-led intervention for hypertension control; empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); efficacy and safety of empagliflozin in hospitalized heart failure patients (EMPULSE); icosapent ethyl versus placebo in outpatients with coronavirus disease 2019 (PREPARE-IT 2); clinical safety, pharmacokinetics, and low-density lipoprotein cholesterol-lowering efficacy of MK-0161, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; and effects of aspirin on dementia and cognitive impairment in the ASCEND trial. Summary: Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention.

AB - Purpose of Review: This review highlights major studies across a broad array of topics presented at the virtual 2021 American Heart Association (AHA) Scientific Sessions. Recent Findings.: Assessed studies examine a remotely delivered hypertension and lipid program in 10,000 patients across a diverse healthcare network; a cluster-randomized trial of a village doctor-led intervention for hypertension control; empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); efficacy and safety of empagliflozin in hospitalized heart failure patients (EMPULSE); icosapent ethyl versus placebo in outpatients with coronavirus disease 2019 (PREPARE-IT 2); clinical safety, pharmacokinetics, and low-density lipoprotein cholesterol-lowering efficacy of MK-0161, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; and effects of aspirin on dementia and cognitive impairment in the ASCEND trial. Summary: Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention.

KW - Aspirin

KW - Atherosclerotic cardiovascular disease

KW - Cardiovascular prevention

KW - Empagliflozin

KW - Heart failure

UR - https://www.scopus.com/pages/publications/85123638706

U2 - 10.1007/s11883-022-00985-0

DO - 10.1007/s11883-022-00985-0

M3 - Review article

C2 - 35080715

AN - SCOPUS:85123638706

SN - 1523-3804

VL - 24

SP - 61

EP - 72

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 1

ER -

Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this